Shots:
- UCB has reported 3yr. BE HEARD trials data where 2 P-III (BE HEARD I & II) trials assessed Bimzelx (320mg; Q2W till Wk. 16, then Q4W) vs PBO in 1,014 adults with mod. to sev. HS; 556 pts completing Wk. 48 entered the OLE (BE HEARD EXT) study
- Among pts with ≥1 draining tunnel at baseline (n=425), 48.2% had none at 1yr. & 62.9% (183/291) at 3yrs.; of those with ≥1 abscess (n=381), 75.3% had none at 1yr. & 83.5% (203/243) at 3yrs.
- Also, 87.8% with no tunnels (n=131) remained so at 1yr & 90.8% (69/76) at 3yrs., while no or mild skin pain increased from 10% (55/551) to 51.7% (287/555) & 65.8% (237/360) at 1 & 3yrs, respectively; data to be presented at the SHSA’25
Ref: UCB | Image: UCB | Press Release
Related News:- UCB Reports the P-III Data of Fenfluramine in CDKL5 Deficiency Disorder (CDD) Patients
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
